Related Experiment Video
Updated: Jan 5, 2026

12:24
Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
Published on: July 17, 2012
12.8K
Simple Aggregation-Induced Emission-Based Multifunctional Fluorescent Dots for Cancer Therapy In Vitro
Xueran Lin1, Junhao Zhao1, Wei Huang1
1Department of Chemistry, Jinan University, Guangzhou, 510632, China.
Chemistry, an Asian Journal
|October 29, 2019
Summary
Novel multifunctional nanoparticles (NPs) were synthesized for cancer therapy. These fluorescent NPs target and induce apoptosis in glioblastoma cells by increasing reactive oxygen species (ROS).
Area of Science:
- Nanotechnology
- Biomedical Engineering
- Materials Science
Background:
- Developing targeted therapies for glioblastoma remains a significant challenge.
- Multifunctional nanoparticles offer potential for combined diagnostic and therapeutic applications.
Purpose of the Study:
- To synthesize and characterize novel multifunctional nanoparticles (NPs) for glioblastoma treatment.
- To investigate the cellular uptake, intracellular fate, and cytotoxic effects of these NPs on U87 glioblastoma cells.
Main Methods:
- Simple mixing of a TICT+AIE featured molecule (TPAPP-CHO) with PBS solution to synthesize NPs.
- Cellular uptake studies using fluorescence microscopy to track NP localization.
- Assessment of NP-induced cytotoxicity and apoptosis via reactive oxygen species (ROS) generation.
Main Results:
- Fluorescent NPs were successfully synthesized and entered U87 cells via endocytosis.
- NPs localized in lysosomes and dissociated, indicating intracellular degradation.
- Synthesized NPs exhibited potent cytotoxicity against U87 glioblastoma cells by inducing apoptosis through ROS overproduction.
Conclusions:
- The synthesized multifunctional nanoparticles are effective in targeting and inducing apoptosis in glioblastoma cells.
- The NPs' ability to generate ROS and trigger apoptosis highlights their therapeutic potential.
- Further research into NP-based therapies for glioblastoma is warranted.

